Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
Our emerging understanding of the IL-2/IL-2R system opens the possibility for more specific immunotherapy of CTCL. This understanding, taken in conjunction with the ability to produce humanized antibodies to the IL-2R subunit by genetic engineering; to arm these antibodies, as well as IL-2 itself with toxins or with alpha- and beta-emitting radionuclides; and to modulate IL-2R subunits to optimize targeting of these agents provides a rational therapeutic strategy for the treatment of IL-2R-expressing CTCL. Although most of these studies were conducted in HTLV-1-associated T-cell lymphomas or CTCL, it is likely that these agents may be applicable to other T-cell lymphomas, including the anaplastic large cell lymphomas, peripheral T-cell lymphomas, and the natural killer lymphomas, because these cells express the IL-2 receptor.
Foss
Francine M
FM
Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA. ffoss@tufts-nemc.org
Waldmann
Thomas A
TA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004167:Diphtheria Toxin / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use; D007376:Interleukin-2 / Q000502:physiology / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000235:genetics; D021122:Protein Subunits; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012176:Retinoids / Q000494:pharmacology / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy
D000911:Antibodies, Monoclonal; D004167:Diphtheria Toxin; D018796:Immunoconjugates; D000922:Immunotoxins; D007376:Interleukin-2; D009363:Neoplasm Proteins; D020033:Protein Isoforms; D021122:Protein Subunits; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D012176:Retinoids; C062518:interleukin 2-diphtheria toxin